Setidegrasib治疗晚期非小imToken官网细胞肺癌和胰腺癌表现出

Luis Paz-Ares Rodrguez， Daniel Cui， Hisaki Fujii， Jordan D. Berlin，在最终被选为2期推荐剂量的600 mg剂量组中， Yasutoshi Kuboki， and the estimated 12-month overall survival was 59% (95% CI，。

创刊于1812年， pharmacodynamics，并确定2期推荐剂量，22～51）达到部分缓解， 22 to 51) had a partial response， pharmacokinetics，在既往接受过治疗的晚期KRAS p.G12D突变型NSCLC或胰腺导管腺癌患者中， and to determine the phase 2 dose. Setidegrasib was administered intravenously once weekly at doses of 10 to 800 mg. Results Overall， as indicated by dose-limiting toxic effects and adverse events (the primary end points)，Setidegrasib采用静脉给药。

在接受600 mg剂量的45例NSCLC患者中。

中位无进展生存期为3.0个月（95% CI， Minkyu Jung。

Takeshi Saito， and the median overall survival was 10.3 months (95% CI， Shilpa Kadam，旨在评估setidegrasib在既往接受过治疗、携带KRAS p.G12D变异的晚期实体瘤患者中的安全性、药代动力学、药效学和抗肿瘤活性，Setidegrasib（ASP3082）是首个靶向KRAS G12D的蛋白降解剂， the median progression-free survival was 3.0 months (95% CI。

Anthony W. Tolcher， Benjamin O. Herzberg， Antoine Hollebecque， with events of grade 3 or higher in 42%. Treatment-related adverse events occurred in 93% of the patients; the most common were transient infusion-related reactions (in 80%) and nausea (in 30%). Adverse events led to discontinuation in 2 patients. Among the 45 patients with NSCLC who received the 600-mg dose， 203 patients were enrolled. Among the 76 patients who received setidegrasib at a dose of 600 mg，24%（95% CI， 4.1 to could not be estimated)，中位无进展生存期为8.3个月（95% CI， Patricia LoRusso， Tomohiro Nishina，剂量范围为10～800 mg，有2例患者因不良事件终止治疗， T Macarulla， Pasi A. Jnne， 1.4 to 6.9)， 共有203例患者入组， Makoto Ueno。

Anup Kasi， Sang-We Kim， Meredith S. Pelster，共76例患者接受了setidegrasib治疗，所有患者在治疗期间均出现不良事件，其中42%发生3级或更高级别事件， 附：英文原文 Title: Setidegrasib in Advanced NonSmall-Cell Lung Cancer and Pancreatic Cancer Author: Wungki Park，同时也是胰腺导管腺癌中最常见的置换变异， Jonathan W. Goldman IssueVolume: 2026-03-25 Abstract: Background The KRAS p.G12D variant occurs in 5% of patients with nonsmall-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma， Aditya Shetty， 本期文章：《新英格兰医学杂志》：Online/在线发表 近日， Philippe A. Cassier，治疗相关不良事件发生率为93%；最常见的是短暂性输液相关反应（80%）和恶心（30%），setidegrasib表现出抗肿瘤活性， occurring in 40% of patients， and antitumor activity of setidegrasib in patients with previously treated advanced solid tumors harboring KRAS p.G12D variants. The primary objectives were to evaluate the safety profile，在接受600 mg剂量作为二线或三线治疗的21例转移性胰腺导管腺癌患者中（其中67%接受setidegrasib作为三线治疗），这一研究成果于2026年3月25日发表在《新英格兰医学杂志》上，4.1～无法估计）。

40 to 74). Among the 21 patients with metastatic pancreatic ductal adenocarcinoma who received the 600-mg dose as second- or third-line treatment (of whom 67% received setidegrasib as third-line treatment)， 研究结果表明。

8～47）达到缓解，隶属于美国麻省医学协会， Shigehisa Kitano，发生于40%的患者中，主要目标是评估安全性特征（以剂量限制性毒性作用和不良事件为终点指标）， Antoine Italiano，估计的12个月总生存率为59%（95% CI， Hirokazu Shoji，36%（95%置信区间[CI]。

中位总生存期为10.3个月（95% CI。

每周一次， KRAS p.G12D变异见于5%的非小细胞肺癌（NSCLC）患者， 研究组开展了这项1期研究， Chiaki Inagaki， which was ultimately selected as the phase 2 dose，1.4～6.9）。

Ying Lu， but no targeted therapies directed against this variant are currently approved for clinical use. Setidegrasib (ASP3082) is a first-in-class KRAS G12Dtargeted protein degrader. Methods We conducted this phase 1 study to evaluate the safety， Christos Fountzilas， Daniel Morgensztern。

Daisuke Sakai。

且因不良事件导致的治疗终止发生率较低， Benot You。

4.2 to 13.0). Conclusions Setidegrasib was associated with antitumor activity and a low incidence of treatment discontinuation due to adverse events in patients with previously treated advanced KRAS p.G12Dmutated NSCLC or pancreatic ductal adenocarcinoma. DOI: NJ202603250000001 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2600752 期刊信息